Drug General Information
Drug ID
D0O6IZ
Former ID
DAP001408
Drug Name
Naphazoline
Synonyms
Antan; Clearine; Nafazolin; Nafazolina; Nafazoline; Naphazolinum; Naphthizine; Opcon; Nafazolina [DCIT]; Nafazoline [Spanish]; Naphazoline Monohydrochloride; Naphazolinum [Latin]; Enamine_000333; Alpha-Naphthylmethyl imidazoline; Ciba 2020/R; Nafazolin (TN); Naphazoline (INN); Naphazoline [INN:BAN]; Naphazolinum [INN-Latin]; AK-968/41090774; 2-(1-Naphthylmethyl)-2-imidazoline; 2-(1-Naphthylmethyl)-4,5-dihydro-1H-imidazole; 2-(Naphthyl-(1')-methyl)imidazolin; 2-(Naphthyl-(1')-methyl)imidazolin [German]; 2-(alpha-Naphthylmethyl)-imidazoline; 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole; 4,5-Dihydro-2-(1-naphthylmethyl)imidazole
Drug Type
Small molecular drug
Indication Corneal vascularity; Hyperaemia; Itching [ICD10:L29] Approved [551871]
Therapeutic Class
Anticancer Agents
Company
Allergan Inc
Structure
Download
2D MOL

3D MOL

Formula
C14H14N2
InChI
InChI=1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16)
InChIKey
CNIIGCLFLJGOGP-UHFFFAOYSA-N
CAS Number
CAS 835-31-4
PubChem Compound ID
PubChem Substance ID
SuperDrug ATC ID
R01AA08; R01AB02; S01GA01
SuperDrug CAS ID
cas=000835314
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Agonist [534898]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
References
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 534898Decongestants in treatment of nasal obstruction. Otolaryngol Pol. 1999;53(3):347-52.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.